Thu, 22 Jan 2015 07:00:00 +0100 Sanofi.com: Last press releases Press releases and press packs are intended to journalists, investors and shareholders. /rss/rss.asp <![CDATA[European Commission Grants Marketing Authorization for Cerdelga® (eliglustat), Genzyme’s Oral Therapy for Gaucher Disease Type 1]]> Thu, 22 Jan 2015 07:00:00 +0100 http://en.sanofi.com/Images/38216_20150122_cerdelgaauth_en.pdf <![CDATA[Merial receives European approval for chewable NexGard® Spectra™]]> Mon, 19 Jan 2015 07:00:00 +0100 http://en.sanofi.com/Images/38206_20150119_NG_Spectra_EUapproval_en.pdf <![CDATA[Sanofi Enters Strategic Manufacturing Collaboration with Boehringer Ingelheim To Produce Biologics ]]> Thu, 15 Jan 2015 07:00:00 +0100 http://en.sanofi.com/Images/38190_20150115_Sanofi_BI_IA_agreement_en.pdf <![CDATA[Sanofi, Regeneron: Praluent (alirocumab) Marketing Authorization Application Accepted for Review by EMA]]> Mon, 12 Jan 2015 07:00:00 +0100 http://en.sanofi.com/Images/38127_20150112_AlirocumabEMAFiling_en.pdf <![CDATA[Sanofi and Regeneron Announce Positive Topline Results from First Phase 3 Trials Evaluating Monthly Dosing of Alirocumab in Patients with Hypercholesterolemia]]> Fri, 09 Jan 2015 07:00:00 +0100 http://en.sanofi.com/Images/38079_20150109_AlirocumabTopline_en.pdf <![CDATA[Merial acquires two major equine health products from Bayer]]> Wed, 17 Dec 2014 07:00:00 +0100 http://en.sanofi.com/Images/37748_20141217_Merial_Equine_Products_EN.pdf <![CDATA[Merial acquires Merck manufacturing facility in Barceloneta, Puerto Rico]]> Thu, 04 Dec 2014 07:15:00 +0100 http://en.sanofi.com/Images/37717_20141204_PuertoRico_en.pdf <![CDATA[Sanofi Receives FDA Approval of Priftin® (rifapentine) Tablets for the Treatment of Latent Tuberculosis Infection]]> Tue, 02 Dec 2014 07:00:00 +0100 http://en.sanofi.com/Images/37707_20141202_priftin_en.pdf <![CDATA[European CHMP Adopts Positive Opinion for Genzyme’s Cerdelga® (eliglustat) Capsules]]> Fri, 21 Nov 2014 01:00:00 +0100 http://en.sanofi.com/Images/37661_20141121_cerdelga_en.pdf <![CDATA[Sanofi and Regeneron Announce that Dupilumab Has Received FDA Breakthrough Therapy Designation in Atopic Dermatitis]]> Thu, 20 Nov 2014 07:30:00 +0100 http://en.sanofi.com/Images/37639_20141120_Dupilumab_AD_Breakthrough_2_en.pdf 5 © Sanofi 2004-2015